Premium
Synthesis of 5‐acetylamino‐4‐[ 11 C]guanidino‐2,6‐anhydro‐3,4,5‐trideoxy‐D‐glycero‐D‐galacto‐non‐2‐enoic acid ([ 11 C]GG167)—an influenza virus neuraminidase inhibitor
Author(s) -
Westerberg G.,
Bamford M.,
Daniel M.J.,
Långström B.,
Sutherland D.R.
Publication year - 1996
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/(sici)1099-1344(199606)38:6<585::aid-jlcr868>3.0.co;2-1
Subject(s) - chemistry , neuraminidase inhibitor , neuraminidase , stereochemistry , cyanogen bromide , biochemistry , enzyme , peptide sequence , medicine , disease , pathology , covid-19 , infectious disease (medical specialty) , gene
The novel influenza virus neuraminidase inhibitor GG167 (5‐acetylamino‐4‐guanidino‐2,6‐anhydro‐3,4,5‐trideoxy‐ D ‐glycero‐ D ‐galacto‐non‐2‐enoic acid) was labelled with 11 C for use in positron emission tomographic studies of drug deposition following intranasal or inhaled administration. [ 11 C]GG167 was obtained within a synthesis time of 50 min via a two‐step procedure, starting from [ 11 C]cyanogen bromide.